Last updated: July 22, 2026
- Iodixanol (marketed as VISIPAQUE; active ingredient: iopromide-free iodinated contrast media) is a mature, niche but defensible radiology product line with pricing that tracks generic erosion patterns, tender dynamics, and supply reliability rather than patent-driven monopolies.
- Financial trajectory is dominated by (1) US tendering and utilization shifts within diagnostic imaging, (2) margin pressure from generic and distributor re-pack competition, and (3) penetration of hospital formularies for iso-osmolar contrast agents versus lower-cost hyperosmolar alternatives.
- Patent influence is limited in many geographies because iodixanol is not a “newness” molecule; the market behaves more like a commodity contrast medium where procurement and contracting drive outcomes.
- Near-term value depends on ecosystem factors: global imaging volumes, reimbursement pressure, radiology department economics, and whether supply constraints or quality recalls hit the supply chain.
What is iodixanol’s market size and demand driver profile?
Iodixanol is used as an intravascular and intrathecal iodinated contrast agent for CT, angiography, and other radiology workflows. Demand is tied to imaging frequency, procedure mix (cardiac and vascular imaging are key), and hospital utilization protocols that prefer iso-osmolar agents in higher-risk patients.
Core demand drivers
- Volume growth in CT and interventional radiology.
- Hospital migration toward iso-osmolar contrast to manage tolerability and nephrotoxicity risk profiles.
- Procedural expansion in cardiovascular and neuroimaging settings.
- Tender and formulary decisions that consolidate purchasing to a small number of contrast suppliers.
Where utilization shifts matter
- Hospitals with contrast-impregnated risk pathways (e.g., chronic kidney disease patients) tend to favor iso-osmolar iodixanol.
- Budget pressure pushes continued substitution toward hyperosmolar generics where protocols allow.
Which clinical settings drive iodixanol consumption most?
- Cardiac and peripheral angiography and related interventional procedures.
- CT angiography and diagnostic CT in high-risk populations.
- Use cases that emphasize iso-osmolar tolerability versus lower-cost alternatives.
How do pricing, tenders, and competitive pressure shape iodixanol revenue?
Iodixanol’s commercial performance is a procurement story. Once multiple suppliers are present, price is set by contracting, not by innovation cycles.
What competitive landscape does iodixanol face?
- Direct equivalents: other iso-osmolar iodinated contrast agents (where marketed) and hyperosmolar agents as substitution candidates.
- Generic erosion: where iodixanol products and presentations are available through generic or alternative sourcing channels, pricing typically compresses.
- Distributor and private label competition can intensify margin pressure.
How does substitution risk change economics by region?
- In markets with centralized procurement, generic availability quickly transfers into price caps and volume re-allocation.
- In decentralized hospital systems, brand loyalty and risk-management protocols can sustain a higher price floor, but tenders still drive declines over time.
What is the financial trajectory for iodixanol: growth vs. decline phases?
Without a drug-specific, time-series revenue dataset in the prompt, the only accurate way to describe trajectory is in market-mechanics terms. Iodixanol should be treated as a mature contrast product in most major markets, with financial outcomes determined by contracting and supply rather than new clinical differentiation.
Likely trajectory pattern in matured contrast categories
- Early growth/installation phase when a brand or branded presentation penetrates hospital formularies.
- Mid-life stabilization as usage becomes routine and annual purchase cycles normalize.
- Erosion phase with generic entrants, parallel sourcing, and increased tender competition.
- Nonlinear shocks from supply disruptions, quality investigations, recalls, or manufacturing outages.
What levers swing performance up or down?
- Formulary inclusion: winning or losing a category tender can rebase quarterly revenue meaningfully.
- Presentation mix: vial sizes and concentration variants influence procurement bundles and customer preferences.
- Reimbursement and budget caps: can shift preference toward the lowest-cost clinically acceptable agent.
- Regulatory or quality events: can cause temporary demand redirection and longer-lasting switching costs.
How does iodixanol compare financially with other iodinated contrast agents?
Iodixanol’s typical positioning is iso-osmolar. That can protect share in higher-acuity or higher-risk segments, but it does not eliminate tender-driven price competition.
Competitive comparison framework
- Iso-osmolar vs. hyperosmolar: iso-osmolar agents often have better tolerability narratives and institutional protocols, but hyperosmolar agents often win on price.
- Brand vs. generic: branded iodixanol can retain share when clinicians follow risk protocols, while generic entrants can capture lower-acuity volume and drive blended price declines.
- Manufacturer scale: large suppliers can sustain supply reliability, which improves contract renewals and reduces lost allocations.
What patents protect iodixanol and how do they affect market exclusivity?
For a mature, commodity-like contrast medium, the patent estate typically has limited incremental effect on pricing once generic or equivalent products enter. The market’s effective exclusivity is mainly controlled by last regulatory approvals, packaging/presentation exclusivity, and any remaining method-of-use or formulation protections that translate into patent barriers for specific dosage presentations.
How to interpret patent influence for iodixanol
- If multiple suppliers sell chemically identical iodixanol formulations, patent barriers do not stop competitive pricing.
- If specific presentations (concentration, volume, or container system) have separate intellectual property, exclusivity may persist for those exact SKUs even when the active ingredient is broadly available.
When does iodixanol lose exclusivity and when do generics enter?
For established iodinated contrast agents, “loss of exclusivity” usually shows up commercially as:
- increased generic or authorized-alternative launches,
- tender price resets,
- and share transfer across institutional buyers.
A precise exclusivity/expiration timeline cannot be stated from the prompt because no Orange Book, patent numbers, or FDA listing identifiers were provided.
What is the Orange Book status of iodixanol?
Iodixanol is an injectable contrast agent. Orange Book status is typically assessed using the listed drug name, route, and dosage form. The prompt does not include the NDC, listed drug name, or Orange Book ID, so the Orange Book listing status cannot be accurately enumerated here.
What formulation patents (concentration, container, stability) can block competition?
Even for mature APIs, competition can be blocked at the presentation level. For contrast media, the most relevant formulation/IP barriers generally relate to:
- concentration and osmolality targets,
- stabilization systems and viscosity characteristics,
- container closure system and stability shelf-life performance,
- manufacturing process controls that impact sterility assurance and lot consistency.
A precise formulation-patent mapping requires patent numbers and cited references that are not included in the prompt.
What patent litigation affects iodixanol generics or biosimilars?
For small-molecule contrast media, the relevant legal pattern is typically Paragraph IV patent certifications (for generics) and any settlement/consent decrees that drive “date-certain” entry schedules.
No litigation docket or settlement terms are provided in the prompt, so a factual litigation assessment cannot be produced.
What generic entry risks exist for iodixanol in the US?
Generic entry risk is driven by:
- availability of a practicable manufacturing route meeting regulatory standards,
- ability to avoid infringing active-ingredient or presentation-specific patents,
- and ability to pass bioequivalence requirements for the injection.
For iodixanol, the market behaves as a procurement commodity; even when patent barriers slow entry for specific SKUs, price pressure can still arrive via alternative product presentations or substitution by hyperosmolar agents.
What FDA regulatory status and approval pathways shape iodixanol availability?
Iodinated contrast media are typically approved through FDA pathways for drug products that demonstrate safety, clinical performance, and chemistry manufacturing controls. Availability is influenced by:
- manufacturing site approvals,
- lot release stability,
- and ongoing compliance with sterile injectables standards.
A timeline of FDA approvals, supplements, and postmarketing regulatory actions cannot be accurately compiled without listed-drug identifiers.
Which companies commercialize iodixanol and how does that affect distribution economics?
Commercial leverage comes from distribution reach, hospital contracting capability, and supply stability. In iodinated contrast categories, major manufacturers typically maintain relationships with large hospital systems through:
- formulary committees,
- multi-year purchasing agreements,
- and service-level commitments (availability, lead times, substitution logistics).
A company-by-company revenue or share forecast cannot be produced without issuer financials, market-share sources, or NDC-level sales data.
What settlement agreements or licensing deals drive iodixanol competition timing?
In mature small-molecule markets, settlement agreements can determine:
- carve-outs by dosage form,
- authorized generic provisions,
- and delayed launches.
No settlement terms or licensing deals are provided in the prompt, so none can be stated.
Market outlook: what will drive iodixanol growth or contraction over the next 3 to 5 years?
Because iodixanol is mature, the outlook is dominated by structural market factors:
- Imaging volume trends: CT utilization and cardiovascular procedural growth.
- Budget environment: payer and provider cost controls.
- Competitive dynamics: generic availability and tender outcomes.
- Regulatory and manufacturing continuity: sterile injectable supply resilience.
- Patient-risk protocols: continued preference for iso-osmolar agents in high-risk cohorts.
Base-case commercial read-through
- Revenue growth is likely limited and could track imaging volumes, with pricing potentially trending down in competitive segments.
- Margin performance is sensitive to contract pricing, input costs (raw materials and sterile manufacturing), and supply disruptions.
Key Takeaways
- Iodixanol’s market behavior is procurement-led and mature-product driven: pricing compression follows tender and generic/alternative entry patterns.
- Financial trajectory is best modeled through imaging utilization, formulary inclusion, and SKU mix rather than a near-term patent cliff.
- Short-term performance hinges on contracting outcomes and supply reliability; long-term performance tracks diagnostic imaging growth and substitution preferences between iso-osmolar and hyperosmolar agents.
- A precise patent-and-exclusivity roadmap requires Orange Book listing identifiers and patent numbers; the prompt does not supply them.
FAQs
- How do hospital tender cycles affect iodixanol pricing and quarterly revenue volatility?
- What factors drive the shift from iso-osmolar iodixanol to lower-cost hyperosmolar contrast agents?
- How do presentation formats (vial size and concentration) influence iodixanol formulary retention?
- What manufacturing or quality events most commonly disrupt iodinated contrast availability and supplier share?
- How does generic entry risk differ between US and non-US markets for iodixanol contrast media?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA public database).
- FDA Guidance documents on drug approval and submissions for injectable drug products and sterile manufacture. (Accessed via FDA public guidance library).
